Welcome to our dedicated page for TXL news (Ticker: TXL), a resource for investors and traders seeking the latest updates and insights on TXL stock.
The TXL news page on Stock Titan focuses on coverage related to Telix Pharmaceuticals Limited (Nasdaq: TXL; ASX: TLX) as it appears in the available information. A key news item links TXL to an agreement under which Telix will acquire a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility from ImaginAb, Inc.
News about TXL in this context centers on radiopharmaceutical and biologics-related developments. The transaction is described as enabling Telix to explore new disease areas using radiotherapeutic technology built on ImaginAb’s minibody-based platform. Statements from ImaginAb highlight that these radiopharmaceutical agents reflect significant scientific effort and that the transaction is seen as a validation of the minibody platform.
Coverage connected to TXL may reference how ImaginAb’s technology has been used in immunotherapy clinical trials, primarily in oncology, and how its agents are designed for quantitative, non-invasive PET and optical imaging of cell surface targets. Examples include CD8 ImmunoPET, which images CD8+ T cells involved in immune responses to tumors and autoimmune diseases, and an Optical PSMA Imaging Agent used to visualize PSMA-positive cancer cells during surgery.
Investors and observers using the TXL news page can review articles that describe this acquisition and related platform details, giving context on how Telix is associated with radiopharmaceutical and imaging technologies through the ImaginAb transaction. Returning to this page allows users to follow additional coverage that may reference this deal and its implications for Telix’s access to biologics and radiopharmaceutical discovery capabilities, as reflected in the available sources.
ImaginAb has agreed to sell its next-generation therapeutic candidates, proprietary biologics technology platform, and protein engineering facility to Telix Pharmaceuticals (ASX: TLX; Nasdaq: TXL). Post-transaction, ImaginAb will focus on developing its CD8 ImmunoPET imaging candidate, currently in Phase 2 clinical trials and licensed by multiple pharmaceutical companies for immunotherapy imaging trials. The company will also continue developing its Phase 2 prostate cancer imaging agent.
The transaction validates ImaginAb's minibody platform technology, which will enable Telix to explore new disease areas with radiotherapeutic technology. The CD8 platform development will continue, with multiple pharmaceutical companies already incorporating the technology in their immuno-oncology clinical trials. Jefferies and Stifel, Nicolaus & Company served as financial advisors for the transaction.